# A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma

> **NCT07138885** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 62 (actual)

## Conditions studied

- Hepatocellular Carcinoma (HCC)
- Second Line Treatment

## Interventions

- **PROCEDURE:** HAI-FOLFOX + bevacizumab + QL1706
- **PROCEDURE:** TACE + bevacizumab + TAS-102 + QL1706

## Key facts

- **NCT ID:** NCT07138885
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-08-01
- **Primary completion:** 2027-07-31
- **Final completion:** 2028-07-31
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2026-04-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07138885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07138885, "A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07138885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*